CARB-X to support lower respiratory tract infection diagnostic by Zeteo

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded Zeteo Tech, Inc. US$1M to execute a workplan for its noninvasive diagnostic platform that aims to evaluate whether exhaled breath can diagnose lower respiratory tract infections (LRTIs) in high-risk populations within critical care environments, including intubated patients with mechanical ventilation.

EnCharge AI Receives Frost & Sullivan’s 2025 Global Technology Trailblazer Recognition for Advancing Analog AI Compute Innovation

Frost & Sullivan is pleased to announce that EnCharge AI has been awarded the 2025 Global Technology Trailblazer Recognition in the advanced analog AI chips sector for its outstanding achievements in innovation, strategy execution, and market disruption. This recognition acknowledges EnCharge AI’s leadership in delivering next-generation compute solutions and redefining AI deployment with transformative performance at the edge.

BioSkryb Genomics Secures Exclusive License to Breakthrough Methylation Patent to Enable the First Single-Cell Five-Base Genome

BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, today announced the execution of an exclusive license to a patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco (CZ Biohub SF) covering a method for combined single-cell DNA methylation and genome variation analyses. The invention originated at Stanford and enables simultaneous, high-resolution readouts of genomic variants and DNA methylation from the same single cell using a non-destructive workflow that preserves DNA integrity.

BioFlyte Awarded U.S. Department of Homeland Security SAFETY Act Designation for Qualified Anti-Terrorism Technology

BioFlyte, a chemical and bioaerosol surveillance firm with a disruptive new class of fieldable chemical and biological threat collection, detection, and identification solutions, today announced that the U.S. Department of Homeland Security (DHS) has awarded the company a SAFETY Act Designation for its aerosol chem/biothreat detection and identification technology. This recognition as a Qualified Anti-Terrorism Technology (QATT) underscores the proven effectiveness and reliability of BioFlyte’s solutions in detecting and mitigating airborne chemical and biological threats, while providing important liability protections under the Support Anti-terrorism by Fostering Effective Technologies (SAFETY) Act of 2002.

US Court Approved Anzu Partners Affiliate to acquire EnvisionTec, Leader in 3D Polymer Printers and Resins, Providing Financing and Stability for Operations

An affiliate of the US industrial technology investor Anzu Partners has been approved by a US court to acquire EnvisionTec GmbH (“EnvisionTec”), which provides customers, suppliers, and employees stability and consistency of operations going forward. Following the court’s approval, which had no objections and is not expected to be subject to any appeals, the parties will now begin implementing the transaction.

US Court Approved Anzu Partners Affiliate to Acquire ExOne, Leader in Digital Sand Casting, Providing Financing and Stability for Operations

Today, an affiliate of the US industrial technology investor Anzu Partners has been approved by a US court to acquire ExOne GmbH and ExOne KK (“ExOne”), which provides customers, suppliers, and employees stability and consistency of operations going forward. Following the court approval, which had no objections and is not expected to be subject to any appeals, the parties will now begin implementing the transaction.

InterVenn Receives AMA PLA Code for Non-Invasive Ovarian Cancer Diagnostic

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, today announced that its flagship test, GlycoKnow™ Ovarian, has received a Proprietary Laboratory Analysis (PLA) code from the American Medical Association (AMA). GlycoKnow Ovarian is a blood-based liquid biopsy diagnostic that helps distinguish ovarian cancer from benign pelvic masses, enabling women to receive the most appropriate care as quickly as possible. The test will be commercially available this fall, aligned with the coding effective date of October 1, 2025.

GelSight® Launches Modulus™: Precision Inspection for Previously Inaccessible Places

GelSight, a pioneer in tactile intelligence technology, today introduced the new GelSight Modulus system to further expand the boundaries of tactile sensing and usher in the next generation of mobile, micron-scale measurement. Modulus brings an entirely new concept to the mobile metrology and Non-Destructive Testing (NDT) space with its swappable lens and camera concept. Modulus brings the accuracy and power that GelSight’s customers have come to expect from its technology into a compact, flexible form factor to help users access previously unreachable areas.

C2A Security and Medcrypt Forge Partnership to Elevate Medical Device Security

C2A Security, the only context-driven product security orchestration platform that addresses the specific needs of software-defined products and cyber-physical systems, and Medcrypt, the leading provider of proactive cybersecurity solutions for medical devices, today announced a strategic partnership to deliver comprehensive security solutions for the rapidly evolving medical and healthcare sector.